Fig. 2: MuHV-4 infection confers clinical protection against PVM primary infection. | Mucosal Immunology

Fig. 2: MuHV-4 infection confers clinical protection against PVM primary infection.

From: A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies

Fig. 2

a–c Thirty days after i.n. Mock or MuHV-4 infection, BALB/c mice were vaccinated with FI-PVM Ags (or ctrl Ags), then challenged i.n. with 3·102 PFU of PVM (or PBS) and followed for weight evolution and clinical score. Experimental outline (a). Analysis of weight curves divided into three successive periods of interest: i, MuHV-4 infection; ii, FI-PVM vaccination; iii, PVM infection (b). Survival of Mock and MuHV-4-infected mice after PVM infection (c). Data are presented as means. ***P ≤ 0.001 (one-way ANOVA and Bonferroni post-tests; only statistics for relevant comparisons are shown). Data are representative of at least three independent experiments with five mice per group.

Back to article page